Jump to main content
Jump to site search


Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer

Author affiliations

Abstract

The therapeutic efficacy of anti-cancer nanomedicines is generally constrained due to limited accumulation in the solid tumors. In this study, we developed a biomimetic nano-carrier to enhance the chemo-therapeutic efficacy of doxorubicin and icotinib in a chemo-resistant non-small cell lung cancer (NSCLC) cell line harboring a mutation in the epidermal growth factor receptor (EGFR). The unique nanomedicine was prepared by coating with targeting cancer cell membrane proteins as highly specific ligands. The resulting biomimetic nanoparticles were highly stable and exhibited superior homologous targeting ability in vitro compared with control groups. In a mouse EGFR-mutated NSCLC xenograft model, intravenous injection of the biomimetic nanomedicine led to a high tumour inhibition rate (87.56%). Histopathological analysis demonstrated that the biomimetic nanomedicine had minimal side effects. Taken together, a cancer cell membrane-based biomimetic drug carrier can significantly enhance drug accumulation and improve therapeutic efficacy in cancers.

Graphical abstract: Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 08 Jul 2019, accepted on 20 Sep 2019 and first published on 01 Oct 2019


Article type: Paper
DOI: 10.1039/C9NR05791A
Nanoscale, 2019, Advance Article

  •   Request permissions

    Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer

    P. Wu, D. Yin, J. Liu, H. Zhou, M. Guo, J. Liu, Y. Liu, X. Wang, Y. Liu and C. Chen, Nanoscale, 2019, Advance Article , DOI: 10.1039/C9NR05791A

Search articles by author

Spotlight

Advertisements